Table 1.
Characteristics of PGx study subjects (n = 23,981).
Table 2.
Overview of pharmacogenetic analysis populations by endpoint.
Table 3.
Effect estimates, population-specific frequency of top-associated common, low frequency and rare variants contributing to baseline and change from baseline Lp-PLA2 enzyme activity.
Table 4.
Summary of PLA2G7 variants observed (allele count and effect size) in STABILITY and SOLID-TIMI 52 studies showing some ethnic group specificity (in bold).
Table 5.
List of significant results for efficacy endpoints (MCE and MI).